Analyst ratings, especially from reputable firms like Cantor Fitzgerald, can significantly impact a stock's short-term performance. An Overweight rating suggests that the analyst believes the stock has a better value proposition relative to the market or its sector. The announcement of an $8 price target represents a positive outlook for Capricor Therapeutics, which could lead to increased investor interest and a potential rise in the stock price.